Pancreatic cancer screening yields moderate benefit, ‘no harms’ for high-risk patients

CHARLOTTE, N.C. — Pancreatic cancer screenings in high-risk individuals identified high-risk lesions in nearly 1% of patients and intermediate-risk pathology in more than 30%, according to data presented at the ACG Annual Scientific Meeting.“Although pancreatic cancer screening has been increasingly studied in the last few years, there is a large variation in the yield, outcomes and harms of this screening in the literature,” Andy Silva-Santisteban, MD, a research fellow at the Center for Advanced Endoscopy at Beth Israel Deaconess Medical Center, told Healio. “ToRead More

Generated by Feedzy